211 related articles for article (PubMed ID: 26748997)
21. Asymmetric 1,5-diarylpenta-1,4-dien-3-ones: Antiproliferative activity in prostate epithelial cell models and pharmacokinetic studies.
Zhang X; Guo S; Chen C; Perez GR; Zhang C; Patanapongpibul M; Subrahmanyam N; Wang R; Keith J; Chen G; Dong Y; Zhang Q; Zhong Q; Zheng S; Wang G; Chen QH
Eur J Med Chem; 2017 Sep; 137():263-279. PubMed ID: 28601720
[TBL] [Abstract][Full Text] [Related]
22. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin.
Deep G; Singh RP; Agarwal C; Kroll DJ; Agarwal R
Oncogene; 2006 Feb; 25(7):1053-69. PubMed ID: 16205633
[TBL] [Abstract][Full Text] [Related]
23. Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models.
Wang R; Zhang X; Chen C; Chen G; Sarabia C; Zhang Q; Zheng S; Wang G; Chen QH
Eur J Med Chem; 2017 Jun; 133():208-226. PubMed ID: 28388523
[TBL] [Abstract][Full Text] [Related]
24. Antiproliferative, antiandrogenic and cytotoxic effects of novel caffeic acid derivatives in LNCaP human androgen-dependent prostate cancer cells.
Sanderson JT; Clabault H; Patton C; Lassalle-Claux G; Jean-François J; Paré AF; Hébert MJ; Surette ME; Touaibia M
Bioorg Med Chem; 2013 Nov; 21(22):7182-93. PubMed ID: 24080105
[TBL] [Abstract][Full Text] [Related]
25. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxicity of 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone in androgen-dependent and -independent prostate cancer cell lines.
Copeland RL; Das JR; Bakare O; Enwerem NM; Berhe S; Hillaire K; White D; Beyene D; Kassim OO; Kanaan YM
Anticancer Res; 2007; 27(3B):1537-46. PubMed ID: 17595773
[TBL] [Abstract][Full Text] [Related]
27. Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer.
Hogan FS; Krishnegowda NK; Mikhailova M; Kahlenberg MS
J Surg Res; 2007 Nov; 143(1):58-65. PubMed ID: 17950073
[TBL] [Abstract][Full Text] [Related]
28. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells.
Davis-Searles PR; Nakanishi Y; Kim NC; Graf TN; Oberlies NH; Wani MC; Wall ME; Agarwal R; Kroll DJ
Cancer Res; 2005 May; 65(10):4448-57. PubMed ID: 15899838
[TBL] [Abstract][Full Text] [Related]
29. Structure-activity relationship and pharmacokinetic studies of 3-O-substitutedflavonols as anti-prostate cancer agents.
Li X; Zhang C; Guo S; Rajaram P; Lee M; Chen G; Fong R; Gonzalez A; Zhang Q; Zheng S; Wang G; Chen QH
Eur J Med Chem; 2018 Sep; 157():978-993. PubMed ID: 30165345
[TBL] [Abstract][Full Text] [Related]
30. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis.
Singh RP; Sharma G; Dhanalakshmi S; Agarwal C; Agarwal R
Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):933-9. PubMed ID: 14504208
[TBL] [Abstract][Full Text] [Related]
31. Aminomethylphosphonic acid and methoxyacetic acid induce apoptosis in prostate cancer cells.
Parajuli KR; Zhang Q; Liu S; You Z
Int J Mol Sci; 2015 May; 16(5):11750-65. PubMed ID: 26006246
[TBL] [Abstract][Full Text] [Related]
32. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells.
Agarwal C; Singh RP; Dhanalakshmi S; Tyagi AK; Tecklenburg M; Sclafani RA; Agarwal R
Oncogene; 2003 Nov; 22(51):8271-82. PubMed ID: 14614451
[TBL] [Abstract][Full Text] [Related]
33. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.
Lin Z; Peng R; Li Z; Wang Y; Lu C; Shen Y; Wang J; Shi G
Int J Mol Med; 2015 Aug; 36(2):424-32. PubMed ID: 26059743
[TBL] [Abstract][Full Text] [Related]
34. 1,2,4-Oxadiazoles: a new class of anti-prostate cancer agents.
Khatik GL; Kaur J; Kumar V; Tikoo K; Nair VA
Bioorg Med Chem Lett; 2012 Mar; 22(5):1912-6. PubMed ID: 22326399
[TBL] [Abstract][Full Text] [Related]
35. Nitrogen-containing derivatives of O-tetramethylquercetin: Synthesis and biological profiles in prostate cancer cell models.
Rajaram P; Jiang Z; Chen G; Rivera A; Phasakda A; Zhang Q; Zheng S; Wang G; Chen QH
Bioorg Chem; 2019 Jun; 87():227-239. PubMed ID: 30904813
[TBL] [Abstract][Full Text] [Related]
36. Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1.
Nambiar DK; Deep G; Singh RP; Agarwal C; Agarwal R
Oncotarget; 2014 Oct; 5(20):10017-33. PubMed ID: 25294820
[TBL] [Abstract][Full Text] [Related]
37. Silibinin prevents prostate cancer cell-mediated differentiation of naïve fibroblasts into cancer-associated fibroblast phenotype by targeting TGF β2.
Ting HJ; Deep G; Jain AK; Cimic A; Sirintrapun J; Romero LM; Cramer SD; Agarwal C; Agarwal R
Mol Carcinog; 2015 Sep; 54(9):730-41. PubMed ID: 24615813
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells.
Thelen P; Wuttke W; Jarry H; Grzmil M; Ringert RH
J Urol; 2004 May; 171(5):1934-8. PubMed ID: 15076315
[TBL] [Abstract][Full Text] [Related]
39. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels.
Singh RP; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
Cancer Res; 2002 Jun; 62(11):3063-9. PubMed ID: 12036915
[TBL] [Abstract][Full Text] [Related]
40. A comparison of novel organoiridium(III) complexes and their ligands as a potential treatment for prostate cancer.
Hockey SC; Barbante GJ; Francis PS; Altimari JM; Yoganantharajah P; Gibert Y; Henderson LC
Eur J Med Chem; 2016 Feb; 109():305-13. PubMed ID: 26802546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
